Our portfolio company Aspivix is developing a technology based on a new approach to replace the cervical tenaculum used in the Intra-Uterine device insertion – which is very painful – with a gentle vacuum suction-based device that guarantees no trauma or bleeding. The Intra-Uterine device (IUD) is the most cost-effective reversible contraception method available […]
Funding, Innovation, Press Release
Annaida Technologies: Providing The Technology To Measure The Inaccessible
03
Dec
Dec
Our portfolio company Annaida is developing a medical device that will allow doctors to screen embryos and determine the most viable to increase chances of success. Their technology can be used to detect and quantify various chemical compounds in microscopic entities, such as human embryos or stem cells, in a non-invasive way. Annaida Technologies […]
25
Nov
Nov
Big congrats to our portfolio company Sedimentum, which has achieved several milestones this year! Among others, they have closed their pre-seed financing round, launched several proof-of-concept studies, their CEO got listed in the Forbes 30 under 30 list, and they have recently won the “Zuger Young Entrepreneur Award 2020.” What this fast-growing start-up has […]
Funding, Innovation
Juvabis Announces Positive Phase 1 Results of EBL-1003 in the Innovative Medicines Initiative’s ENABLE Consortium
24
Nov
Nov
Our portfolio company Juvabis AG announces the completion and positive results from its first-in-human single intravenous dose Phase 1 study in healthy volunteers. EBL-1003 (apramycin) was safe and well-tolerated in all dose groups. The results support further clinical development of EBL-1003 in patients. Juvabis AG is a clinical-stage biopharmaceutical company focused on discovering and […]
20
Nov
Nov
We are close to the end of the World Antimicrobial Awareness Week. Therefore today, we want to present to you two of our portfolio companies who are also fighting this battle. Juvabis is developing an aminoglycoside antibiotic-combination therapy and PerioTrap has developed a new specific antibiotic that exclusively affects the pathogenic bacteria of its target indication. By now we all know that […]
19
Nov
Nov
The start-ups Phagomed, Opterion, ACTHERA, and Inura have pitched today to a group of international investors. At HEMEX, we are very happy about this successful series of 2020 Pitch Events, which have resulted in numerous investment opportunities At HEMEX, we firmly believe in a kind of Pitch Event format where start-ups get the opportunity […]
18
Nov
Nov
The World Antimicrobial Awareness Week (WAAW) starts today, and this year’s slogan highlights the importance of encouraging best practices when it comes to using antimicrobials. Our portfolio company Resistell is helping to reduce the spreading of antibiotic resistance with their rapid Antimicrobial Susceptibility Testing. The World Antimicrobial Awareness Week (WAAW) is a global action […]
Competitions, Funding, Innovation
Swiss Innovation Challenge 2020 Online Award-Winning Ceremony: Sustainability, antimicrobial resistance, and mobile technology
16
Nov
Nov
The winner of the SIC is AgroSustain, a Start-up aiming to reduce food waste and support organic food production. The second position is claimed by Resistell, which has developed the world’s fastest antibiogram, and the third position is for Help2type, who created a mobile keyboard for blind and visually impaired people. The Swiss Innovation Challenge 2020 […]
11
Nov
Nov
The award ceremony for the Swiss Innovation Challenge 2020 will take place online next Monday, November 16th, 2020, from 4.30 p.m. to 5 p.m. As in previous years, the winning project will emerge from the three finalist projects determined at the “Swiss Innovation Challenge Final Pitch.” Due to the current Coronavirus situation, the Swiss […]